Ian Bickley bought $100k of VRA
director at Vera Bradley, Inc.. 53,722 shares at an average of $1.86, traded Jun 12, 2025, filed Jun 13, 2025.
Score components
- +15RoleDirector
- +10Trade size$100k at market
- +10Relative to holdingsHoldings up 135%
- +18Price context8% above the 52-week low; 69% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-017219, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 12, 2025 | POpen-market purchase Common Shares | +53,722 | $1.86 | $100k | 93,628 | Jun 13, 2025 |
Related signals
Other insiders at Vera Bradley, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | VRAbuy Vera Bradley, Inc. | Ivan Brockman director | $50k 10,000 shares | +400% | |
| 23Weak | VRAbuy Vera Bradley, Inc. | Ivan Brockman director | $10k 2,500 shares | - | |
| 36Weak | VRAbuy Vera Bradley, Inc. | Ian Bickley director | $103k 53,000 shares | +7% | |
| 68Notable | Vera Bradley, Inc. | Andrew Meslow director | $475k 253,094 shares | +540% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.